Regular paper
Expression of Fos-like immunoreactivity by yohimbine and clonidine in the rat brain

https://doi.org/10.1016/0922-4106(92)90084-9Get rights and content

Abstract

To elucidate the role of α2-adrenoceptors in transcriptional control in the rat brain, we localized the Fos-like immunoreactivity (Fos-LI) induced by α2-adrenoceptor agonists and by an antagonist. Injections of yohimbine (5 mg/kg, i.p.) into rats led to the induction of Fos-LI in areas with a dense α2-adrenoceptor binding such as the locus coeruleus, the bed nucleus of stria terminalis, the central nucleus of amygdaloid complex, the paraventricular nucleus, the nucleus tractus solitarius, and ventrolateral medulla oblongata. Clonidine (500 μg/kg, i.p.) suppressed the Fos expression by yohimbine in these nuclei, and clonidine (100 μg/kg, i.p.) or guanabenz (4 mg/kg, i.p.) induced Fos-LI in oxytocin neurons in the paraventricular and supraoptic nuclei in the hypothalamus. Thus, the α2-adrenoceptor is involved in transcriptional control via Fos expression in neurons related to autonomic and other functions.

References (35)

  • J.J. Morgan et al.

    Stimulus-transcription coupling in neurons: role of cellular immediate-early genes

    Trends Neurosci.

    (1989)
  • Y. Nakabeppu et al.

    A naturally occurring truncated form of FosB that inhibits Fos/Jun transcription activity

    Cell

    (1991)
  • I.M. Verma et al.

    Proto-oncogene fos: complex but versatile regulation

    Cell

    (1987)
  • R.E. Zigmond et al.

    Increased tyrosine hydroxylase activity in the locus coeruleus of rat brain stem after reserpine treatment and cold stress

    Brain Res.

    (1974)
  • C.L. Boyajian et al.

    Pharmacological evidence for alpha-2 adrenoceptor heterogencity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain

    J. Pharmacol. Exp. Ther.

    (1987)
  • C.L. Boyajian et al.

    Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain

    J. Pharmacol. Exp. Ther.

    (1987)
  • S. Ceccatelli et al.

    Expression of Fos immunoreactivity in transmitter-characterized neurons after stress

  • Cited by (24)

    • Nucleus incertus Orexin<inf>2</inf> receptors mediate alcohol seeking in rats

      2016, Neuropharmacology
      Citation Excerpt :

      Interestingly yohimbine (1 mg/kg i.p.) itself did not evoke Fos-IR in OX neurons. Previous studies have shown variable impact of yohimbine (5 mg/kg i.p) on Fos activation, Singewald et al. (2003) observed an increase of Fos in the LH, but Tsujino et al. (1992) observed no change (Singewald et al., 2003; Tsujino et al., 1992). Footshock increases OX Fos in the DMH, PeF or rats (Harris et al., 2005) and DMH, PeF and LH of mice (Watanabe et al., 2005).

    • Modulation of cannabinoid signaling by amygdala α<inf>2</inf>-adrenergic system in fear conditioning

      2016, Behavioural Brain Research
      Citation Excerpt :

      Yohimbine is specific in its antagonism of the α2 “inhibitory” subtype, and is used clinically as a probe to identify abnormal physiological and affective responses to increased noradrenergic signaling. Although yohimbine has been suggested or reported to interact with receptors for other monoamines [33], the α2 receptor agonist clonidine reverses yohimbine-induced anxiety, and the ability of yohimbine to increase cFos expression and establishment of long-term memory formation in the cortex, amygdala, and other brain regions in rats is attenuated or blocked by pretreatment with clonidine or propranolol, a post-synaptic β-adrenergic receptor antagonist [34–36]. Yohimbine increases neurotransmitter release from noradrenergic axon terminals by blocking presynaptic feedback inhibition of release, and simultaneously reduces the ability of NE to exert inhibitory post-synaptic effects while leaving the excitatory effects of NE at postsynaptic α1 and β receptors unopposed [37].

    • Yohimbine anxiogenesis in the elevated plus maze is disrupted by bilaterally disconnecting the bed nucleus of the stria terminalis from the central nucleus of the amygdala

      2012, Neuroscience
      Citation Excerpt :

      Among adrenergic receptors, YO is specific in its antagonism of the α2 “inhibitory” subtype, and was used in this study as an experimental tool to increase excitatory NA receptor signaling. Although YO has been suggested or reported to interact with receptors for other monoamines (Johnston and File, 1989; Winter and Rabin, 1992; Millan et al., 2000), the α2 receptor agonist clonidine reverses YO-induced anxiety, and the ability of YO to increase cFos expression in the cortex, amygdala, and other brain regions in rats is attenuated or blocked by pretreatment with clonidine or propranolol, a post-synaptic β-adrenergic receptor antagonist (Charney et al., 1983; Gubits et al., 1989; Johnston and File, 1989; Bing et al., 1992; Tsujino et al., 1992). Nevertheless, interpretation of our results does not depend on whether or not YO’s actions are limited to increased transmitter release from NA terminals and increased post-synaptic adrenergic receptor signaling.

    View all citing articles on Scopus
    View full text